Physicians' Academy for Cardiovascular Education

PCSK9 Inhibition: Science, Outcomes & Guidance

Meeting report with video, highlights and slides of a PACE-CME symposium held during ESC 2018 in Munich on PCSK9 inhibition and update in science, outcome & guidance - videos and online CME will be added soon

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands
Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.

Meeting Impression | PCSK9 inhibition: Science, outcomes & guidance

August 25, 2018 - Munich, Germany
August 25, 2018 - Munich, Germany

Download the meeting impression of this PACE symposium during ESC 2018, which reviewed PCSK9 inhibition with regard to science, outcomes and guidance.

Summary | Targeting PCSK9 in clinical practice: Guidance & future

Munich, Berlin - August 25, 2018

This is a summary of the presentation by John Kastelein, in which he discusses targeting PCSK9 in clinical practice, focusing on issues surrounding prescription of PCSK9 monoclonal antibodies.

Summary | Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

Munich, Berlin - August 25, 2018

This is a summary of the presentation by Jennifer Robinson, in which she explains that the greatest benefit of PCSK9 antibodies can be obtained at higher LDL-c levels, as seen in high-risk populations.

Summary | PCSK9 as target for treatment: The genetic validation

Munich, Berlin - August 25, 2018

This is a summary of the presentation by Brian Ference, in which he shows data suggesting that PCSK9 inhibitors and statins have biologically and therapeutically equivalent effects on the risk of CVD.

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA
Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK
Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.

Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.

Slides: Targeting PCSK9 in clinical practice: Guidance & future

Presentation Prof. John Kastelein

Slides (presentation) - Aug. 25, 2018 - ESC Congress 2018, Munich - John Kastelein, MD - Amsterdam, The Netherlands
This lecture by prof. John Kastelein was part of a CME accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

Presentation Prof. Jennifer Robinson

Slides (presentation) - Aug. 25, 2018 - ESC Congress 2018, Munich - Jennifer Robinson, MD - Iowa, USA
This lecture by prof. Jennifer Robinson was part of a CME accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: PCSK9 as target for treatment: The genetic validation

Presentation Prof. Brian Ference

Slides (presentation) - Aug. 25, 2018 - ESC Congress 2018, Munich - Brian Ference, MD - Cambridge, UK
This lecture by prof Brian Ference was part of a CME accredited symposium

Slides as educational service to PACE members and meeting participants

PCSK9 Inhibition: Science, Outcomes & Guidance
PCSK9 Inhibition: Science, Outcomes & Guidance